FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306404736> ?p ?o ?g. }

• W4306404736 endingPage "S1409" @default.
• W4306404736 startingPage "S1409" @default.
• W4306404736 abstract "BackgroundThe deregulation of epigenetic mechanisms is considered the main agent in the development of GBM. One of the enzymes involved in epigenetic alternation and cancer development are (HDAC) by removal acetyl group from histone and creating condensed chromatin that suppresses transcription gene to histone and non-histone proteins involved in tumorigenesis. Histone deacetylase inhibitors (HADCi) are the most common therapeutic methods for many types of cancer treatments that enabled researchers to study and develop HDAC inhibitors. Mocetinostat, also known as MGCD0103 is an isotype-selective (HDACi) that selectively inhibits HDACs 1−3 and 11 in vitro.MethodsTo demonstrate the role of MGCD0103 to inhibit growth and induce apoptosis in glioblastoma cells. We used different concentrations of MGCD0103 (0.5,1.0,1,5,2.0,2.5) μM on two types of glioblastoma C6 and T98G.ResultsThe study showed that MGCD0103 exhibited a potent inhibitory role in the treatment of glioblastoma cancer cells. The MGCD0103103 in a dose- and time-dependent manner are actively contributed to inhibiting cell proliferation, invasion, angiogenesis and induce apoptosis and differentiation through modulating in the molecular mechanism for many pathways inside of cells such as suppression of PI3K/AKT pathway and HDAC1 responsible of many biological processes in cancer initiation and progression, and activation intrinsic and extrinsic pathway involved in apoptosis by upregulating pro-apoptotic proteins BAX and downregulating anti-apoptotic proteins, Bid, Bcl2. Also, the mocetinostat increases the expression of the tumor suppressor gene and decreases the expression of the E2f1 transcription factor. In addition to MGCDO103 induced differentiation by activating differentiation marker GFAP and inhibiting differentiation marker (Id2, N-Myc).ConclusionsThe MGCD0103 is a promising anticancer agent that plays an important role treatment of glioblastoma cells.Legal entity responsible for the studyF. Khathayer.FundingHas not received any funding.DisclosureThe author has declared no conflicts of interest. BackgroundThe deregulation of epigenetic mechanisms is considered the main agent in the development of GBM. One of the enzymes involved in epigenetic alternation and cancer development are (HDAC) by removal acetyl group from histone and creating condensed chromatin that suppresses transcription gene to histone and non-histone proteins involved in tumorigenesis. Histone deacetylase inhibitors (HADCi) are the most common therapeutic methods for many types of cancer treatments that enabled researchers to study and develop HDAC inhibitors. Mocetinostat, also known as MGCD0103 is an isotype-selective (HDACi) that selectively inhibits HDACs 1−3 and 11 in vitro. The deregulation of epigenetic mechanisms is considered the main agent in the development of GBM. One of the enzymes involved in epigenetic alternation and cancer development are (HDAC) by removal acetyl group from histone and creating condensed chromatin that suppresses transcription gene to histone and non-histone proteins involved in tumorigenesis. Histone deacetylase inhibitors (HADCi) are the most common therapeutic methods for many types of cancer treatments that enabled researchers to study and develop HDAC inhibitors. Mocetinostat, also known as MGCD0103 is an isotype-selective (HDACi) that selectively inhibits HDACs 1−3 and 11 in vitro. MethodsTo demonstrate the role of MGCD0103 to inhibit growth and induce apoptosis in glioblastoma cells. We used different concentrations of MGCD0103 (0.5,1.0,1,5,2.0,2.5) μM on two types of glioblastoma C6 and T98G. To demonstrate the role of MGCD0103 to inhibit growth and induce apoptosis in glioblastoma cells. We used different concentrations of MGCD0103 (0.5,1.0,1,5,2.0,2.5) μM on two types of glioblastoma C6 and T98G. ResultsThe study showed that MGCD0103 exhibited a potent inhibitory role in the treatment of glioblastoma cancer cells. The MGCD0103103 in a dose- and time-dependent manner are actively contributed to inhibiting cell proliferation, invasion, angiogenesis and induce apoptosis and differentiation through modulating in the molecular mechanism for many pathways inside of cells such as suppression of PI3K/AKT pathway and HDAC1 responsible of many biological processes in cancer initiation and progression, and activation intrinsic and extrinsic pathway involved in apoptosis by upregulating pro-apoptotic proteins BAX and downregulating anti-apoptotic proteins, Bid, Bcl2. Also, the mocetinostat increases the expression of the tumor suppressor gene and decreases the expression of the E2f1 transcription factor. In addition to MGCDO103 induced differentiation by activating differentiation marker GFAP and inhibiting differentiation marker (Id2, N-Myc). The study showed that MGCD0103 exhibited a potent inhibitory role in the treatment of glioblastoma cancer cells. The MGCD0103103 in a dose- and time-dependent manner are actively contributed to inhibiting cell proliferation, invasion, angiogenesis and induce apoptosis and differentiation through modulating in the molecular mechanism for many pathways inside of cells such as suppression of PI3K/AKT pathway and HDAC1 responsible of many biological processes in cancer initiation and progression, and activation intrinsic and extrinsic pathway involved in apoptosis by upregulating pro-apoptotic proteins BAX and downregulating anti-apoptotic proteins, Bid, Bcl2. Also, the mocetinostat increases the expression of the tumor suppressor gene and decreases the expression of the E2f1 transcription factor. In addition to MGCDO103 induced differentiation by activating differentiation marker GFAP and inhibiting differentiation marker (Id2, N-Myc). ConclusionsThe MGCD0103 is a promising anticancer agent that plays an important role treatment of glioblastoma cells. The MGCD0103 is a promising anticancer agent that plays an important role treatment of glioblastoma cells." @default.
• W4306404736 created "2022-10-17" @default.
• W4306404736 creator A5088016831 @default.
• W4306404736 date "2022-10-01" @default.
• W4306404736 modified "2023-10-09" @default.
• W4306404736 title "85P Mocetinostat (MGCD0103) or MG0103 is an isotype-selective histone deacetylase (HDAC) inhibitor induce apoptosis and suppress tumor in glioblastoma cell lines C6 and T98G" @default.
• W4306404736 doi "https://doi.org/10.1016/j.annonc.2022.09.086" @default.
• W4306404736 hasPublicationYear "2022" @default.
• W4306404736 type Work @default.
• W4306404736 citedByCount "1" @default.
• W4306404736 countsByYear W43064047362023 @default.
• W4306404736 crossrefType "journal-article" @default.
• W4306404736 hasAuthorship W4306404736A5088016831 @default.
• W4306404736 hasBestOaLocation W43064047361 @default.
• W4306404736 hasConcept C104317684 @default.
• W4306404736 hasConcept C190283241 @default.
• W4306404736 hasConcept C2778305200 @default.
• W4306404736 hasConcept C502942594 @default.
• W4306404736 hasConcept C55493867 @default.
• W4306404736 hasConcept C62112901 @default.
• W4306404736 hasConcept C64927066 @default.
• W4306404736 hasConcept C86339819 @default.
• W4306404736 hasConcept C86803240 @default.
• W4306404736 hasConceptScore W4306404736C104317684 @default.
• W4306404736 hasConceptScore W4306404736C190283241 @default.
• W4306404736 hasConceptScore W4306404736C2778305200 @default.
• W4306404736 hasConceptScore W4306404736C502942594 @default.
• W4306404736 hasConceptScore W4306404736C55493867 @default.
• W4306404736 hasConceptScore W4306404736C62112901 @default.
• W4306404736 hasConceptScore W4306404736C64927066 @default.
• W4306404736 hasConceptScore W4306404736C86339819 @default.
• W4306404736 hasConceptScore W4306404736C86803240 @default.
• W4306404736 hasLocation W43064047361 @default.
• W4306404736 hasOpenAccess W4306404736 @default.
• W4306404736 hasPrimaryLocation W43064047361 @default.
• W4306404736 hasRelatedWork W1565061379 @default.
• W4306404736 hasRelatedWork W1989395477 @default.
• W4306404736 hasRelatedWork W2014198377 @default.
• W4306404736 hasRelatedWork W2380755462 @default.
• W4306404736 hasRelatedWork W2471519923 @default.
• W4306404736 hasRelatedWork W2755853517 @default.
• W4306404736 hasRelatedWork W2908166538 @default.
• W4306404736 hasRelatedWork W3148810057 @default.
• W4306404736 hasRelatedWork W3150682115 @default.
• W4306404736 hasRelatedWork W3152233030 @default.
• W4306404736 hasVolume "33" @default.
• W4306404736 isParatext "false" @default.
• W4306404736 isRetracted "false" @default.
• W4306404736 workType "article" @default.